Literature DB >> 9582273

Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells.

T van Agthoven1, T L van Agthoven, A Dekker, P J van der Spek, L Vreede, L C Dorssers.   

Abstract

The antiestrogen tamoxifen is important in the treatment of hormone-dependent breast cancer, although development of resistance is inevitable. To unravel the molecular mechanisms of antiestrogen resistance, a search for involved genes was initiated. Retrovirus-mediated insertional mutagenesis was applied to human ZR-75-1 breast cancer cells. Infected cells were subjected to tamoxifen selection and a panel of resistant cell clones was established. Screening for a common integration site resulted in the identification of a novel gene designated BCAR3. Transfer of this locus by cell fusion or transfection of the BCAR3 cDNA to ZR75-1 and MCF-7 cells induces antiestrogen resistance. BCAR3 represents a putative SH2 domain-containing protein and is partly homologous to the cell division cycle protein CDC48.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9582273      PMCID: PMC1170620          DOI: 10.1093/emboj/17.10.2799

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  45 in total

1.  Identification of a novel breast-cancer-anti-estrogen-resistance (BCAR2) locus by cell-fusion-mediated gene transfer in human breast-cancer cells.

Authors:  L C Dorssers; J Veldscholte
Journal:  Int J Cancer       Date:  1997-08-07       Impact factor: 7.396

Review 2.  Retroviral mutagenesis of cellular oncogenes: a review with insights into the mechanisms of insertional activation.

Authors:  H J Kung; C Boerkoel; T H Carter
Journal:  Curr Top Microbiol Immunol       Date:  1991       Impact factor: 4.291

Review 3.  An analysis of vertebrate mRNA sequences: intimations of translational control.

Authors:  M Kozak
Journal:  J Cell Biol       Date:  1991-11       Impact factor: 10.539

4.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

5.  Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer.

Authors:  S Nicholson; J R Sainsbury; P Halcrow; P Chambers; J R Farndon; A L Harris
Journal:  Lancet       Date:  1989-01-28       Impact factor: 79.321

6.  Breast tumor cell lines from pleural effusions.

Authors:  R Cailleau; R Young; M Olivé; W J Reeves
Journal:  J Natl Cancer Inst       Date:  1974-09       Impact factor: 13.506

7.  Hormone dependency of breast cancer.

Authors:  E V Jensen
Journal:  Cancer       Date:  1981-05-15       Impact factor: 6.860

8.  Genetic transfer of non-P-glycoprotein-mediated multidrug resistance (MDR) in somatic cell fusion: dissection of a compound MDR phenotype.

Authors:  E W Eijdems; P Borst; A P Jongsma; S de Jong; E G de Vries; M van Groenigen; C H Versantvoort; A W Nieuwint; F Baas
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

9.  Establishment and characterization of three new continuous cell lines derived from human breast carcinomas.

Authors:  L W Engel; N A Young; T S Tralka; M E Lippman; S J O'Brien; M J Joyce
Journal:  Cancer Res       Date:  1978-10       Impact factor: 12.701

Review 10.  Towards a molecular basis for tamoxifen resistance in breast cancer.

Authors:  S R Johnston; M Dowsett; I E Smith
Journal:  Ann Oncol       Date:  1992-07       Impact factor: 32.976

View more
  46 in total

1.  Splice variants and expression patterns of SHEP1, BCAR3 and NSP1, a gene family involved in integrin and receptor tyrosine kinase signaling.

Authors:  Virginie S Vervoort; Séverine Roselli; Robert G Oshima; Elena B Pasquale
Journal:  Gene       Date:  2007-01-08       Impact factor: 3.688

2.  Nanometer-scale mapping and single-molecule detection with color-coded nanoparticle probes.

Authors:  Amit Agrawal; Rajesh Deo; Geoffrey D Wang; May D Wang; Shuming Nie
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-27       Impact factor: 11.205

Review 3.  Biological determinants of endocrine resistance in breast cancer.

Authors:  Elizabeth A Musgrove; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2009-09       Impact factor: 60.716

4.  BCAR3/AND-34 can signal independent of complex formation with CAS family members or the presence of p130Cas.

Authors:  Pierre Vanden Borre; Richard I Near; Anthony Makkinje; Gustavo Mostoslavsky; Adam Lerner
Journal:  Cell Signal       Date:  2011-01-22       Impact factor: 4.315

5.  Association of the breast cancer antiestrogen resistance protein 1 (BCAR1) and BCAR3 scaffolding proteins in cell signaling and antiestrogen resistance.

Authors:  Yann Wallez; Stefan J Riedl; Elena B Pasquale
Journal:  J Biol Chem       Date:  2014-02-28       Impact factor: 5.157

Review 6.  Pathways to tamoxifen resistance.

Authors:  Rebecca B Riggins; Randy S Schrecengost; Michael S Guerrero; Amy H Bouton
Journal:  Cancer Lett       Date:  2007-05-01       Impact factor: 8.679

7.  NSP-CAS Protein Complexes: Emerging Signaling Modules in Cancer.

Authors:  Yann Wallez; Peter D Mace; Elena B Pasquale; Stefan J Riedl
Journal:  Genes Cancer       Date:  2012-05

8.  Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer.

Authors:  M F E Godinho; A M Sieuwerts; M P Look; D Meijer; J A Foekens; L C J Dorssers; T van Agthoven
Journal:  Br J Cancer       Date:  2010-09-21       Impact factor: 7.640

9.  BCAR3 regulates Src/p130 Cas association, Src kinase activity, and breast cancer adhesion signaling.

Authors:  Natasha R Schuh; Michael S Guerrero; Randy S Schrecengost; Amy H Bouton
Journal:  J Biol Chem       Date:  2009-11-23       Impact factor: 5.157

10.  CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer.

Authors:  T van Agthoven; A M Sieuwerts; J Veldscholte; M E Meijer-van Gelder; M Smid; A Brinkman; A T den Dekker; I M Leroy; W F J van Ijcken; S Sleijfer; J A Foekens; L C J Dorssers
Journal:  Br J Cancer       Date:  2009-11-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.